| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2653926 | Intensive and Critical Care Nursing | 2006 | 4 Pages |
Abstract
SummaryCaspofungin is a member of a new class of antifungals called Echinocandins and is the first to have marketing authorisation in the United Kingdom.This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of caspofungin. The article also discusses the warnings and precautions associated with the use of this drug.Caspofungin is an effective treatment option in the management of fungal infections.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Simon Keady, Meera Thacker,